Research ExplorerPublicationsRecombinant vesicular stomatitis virus vector vaccines for W...

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Standard

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. / Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.

In: HUM VACC IMMUNOTHER, Vol. 15, No. 10, 2019, p. 2269-2285.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Fathi, A, Dahlke, C & Addo, MM 2019, 'Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens', HUM VACC IMMUNOTHER, vol. 15, no. 10, pp. 2269-2285. https://doi.org/10.1080/21645515.2019.1649532

APA

Fathi, A., Dahlke, C., & Addo, M. M. (2019). Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. HUM VACC IMMUNOTHER, 15(10), 2269-2285. https://doi.org/10.1080/21645515.2019.1649532

Vancouver

Fathi A, Dahlke C, Addo MM. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. HUM VACC IMMUNOTHER. 2019;15(10):2269-2285. https://doi.org/10.1080/21645515.2019.1649532

Bibtex

@article{c20cac920a814b4ab7b9da54740f279c,
title = "Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens",
abstract = "The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.",
keywords = "Clinical Trials as Topic, Communicable Diseases, Emerging/prevention & control, Ebola Vaccines/immunology, Genetic Vectors, Hemorrhagic Fever, Ebola/prevention & control, Humans, Vaccines, Attenuated, Vesiculovirus, Viral Proteins/immunology, Viral Vaccines/immunology, Virus Diseases/prevention & control, World Health Organization",
author = "Anahita Fathi and Christine Dahlke and Addo, {Marylyn M}",
note = "Letter",
year = "2019",
doi = "10.1080/21645515.2019.1649532",
language = "English",
volume = "15",
pages = "2269--2285",
journal = "HUM VACC IMMUNOTHER",
issn = "2164-5515",
publisher = "LANDES BIOSCIENCE",
number = "10",

}

RIS

TY - JOUR

T1 - Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

AU - Fathi, Anahita

AU - Dahlke, Christine

AU - Addo, Marylyn M

N1 - Letter

PY - 2019

Y1 - 2019

N2 - The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.

AB - The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.

KW - Clinical Trials as Topic

KW - Communicable Diseases, Emerging/prevention & control

KW - Ebola Vaccines/immunology

KW - Genetic Vectors

KW - Hemorrhagic Fever, Ebola/prevention & control

KW - Humans

KW - Vaccines, Attenuated

KW - Vesiculovirus

KW - Viral Proteins/immunology

KW - Viral Vaccines/immunology

KW - Virus Diseases/prevention & control

KW - World Health Organization

U2 - 10.1080/21645515.2019.1649532

DO - 10.1080/21645515.2019.1649532

M3 - SCORING: Review article

C2 - 31368826

VL - 15

SP - 2269

EP - 2285

JO - HUM VACC IMMUNOTHER

JF - HUM VACC IMMUNOTHER

SN - 2164-5515

IS - 10

ER -